##  [Novartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept](/us-en/news/media-releases/novartis-phase-iii-beovu-data-show-potential-fluid-resolution-more-diabetic-macular-edema-patients-fewer-injections-versus-aflibercept-0 "Novartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept") 

  May 01, 2021